{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:36:11Z","timestamp":1789731371544,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T00:00:00Z","timestamp":1312416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00520-011-1237-2","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T23:21:38Z","timestamp":1312327298000},"page":"1491-1497","source":"Crossref","is-referenced-by-count":62,"title":["Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study"],"prefix":"10.1007","volume":"20","author":[{"given":"Ya-Hsu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Kou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Shone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shung-Haur","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Kai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Tzu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chueh-Chuan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hwai","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huey-Ling","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Jen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,4]]},"reference":[{"key":"1237_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(05)17706-X","volume":"365","author":"J Weitz","year":"2005","unstructured":"Weitz J, Koch M, Debus J et al (2005) Colorectal cancer. Lancet 365:153\u2013165","journal-title":"Lancet"},{"key":"1237_CR2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","volume":"352","author":"JA Meyerhardt","year":"2005","unstructured":"Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476\u2013487","journal-title":"N Engl J Med"},{"key":"1237_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17425255.3.2.281","volume":"3","author":"GP Kim","year":"2007","unstructured":"Kim GP, Erlichman C (2007) Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 3:281\u2013294","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1237_CR4","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"key":"1237_CR5","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"1237_CR6","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084\u20132091","journal-title":"J Clin Oncol"},{"key":"1237_CR7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2014a GERCOR study. J Clin Oncol 24:394\u2013400","journal-title":"J Clin Oncol"},{"key":"1237_CR8","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","volume":"20","author":"RH Wilson","year":"2002","unstructured":"Wilson RH, Lehky T, Thomas RR et al (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767\u20131774","journal-title":"J Clin Oncol"},{"key":"1237_CR9","first-page":"13","volume":"25","author":"JM Extra","year":"1998","unstructured":"Extra JM, Marty M, Brienza S et al (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13\u201322","journal-title":"Semin Oncol"},{"key":"1237_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","volume":"30","author":"A Grothey","year":"2003","unstructured":"Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30:5\u201313","journal-title":"Semin Oncol"},{"key":"1237_CR11","first-page":"249","volume":"1","author":"MW Saif","year":"2005","unstructured":"Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1:249\u2013258","journal-title":"Ther Clin Risk Manag"},{"key":"1237_CR12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","volume":"44","author":"S Wolf","year":"2008","unstructured":"Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507\u20131515","journal-title":"Eur J Cancer"},{"key":"1237_CR13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00520-009-0740-1","volume":"18","author":"R Cathomas","year":"2010","unstructured":"Cathomas R, Koberle D, Ruhstaller T et al (2010) Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18:1263\u20131270","journal-title":"Support Care Cancer"},{"key":"1237_CR14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4088\/JCP.v63n0407","volume":"63","author":"MJ Detke","year":"2002","unstructured":"Detke MJ, Lu Y, Goldstein DJ et al (2002) Duloxetine, 60\u00a0mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308\u2013315","journal-title":"J Clin Psychiatry"},{"key":"1237_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/JCP.v63n0309","volume":"63","author":"DJ Goldstein","year":"2002","unstructured":"Goldstein DJ, Mallinckrodt C, Lu Y et al (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63:225\u2013231","journal-title":"J Clin Psychiatry"},{"key":"1237_CR16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.jcp.0000132448.65972.d9","volume":"24","author":"DJ Goldstein","year":"2004","unstructured":"Goldstein DJ, Lu Y, Detke MJ et al (2004) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24:389\u2013399","journal-title":"J Clin Psychopharmacol"},{"key":"1237_CR17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ et al (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109\u2013118","journal-title":"Pain"},{"key":"1237_CR18","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Pritchett YL, D\u2019Souza DN et al (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411\u20131420","journal-title":"Neurology"},{"key":"1237_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","volume":"6","author":"J Raskin","year":"2005","unstructured":"Raskin J, Pritchett YL, Wang F et al (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6:346\u2013356","journal-title":"Pain Med"},{"key":"1237_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(83)90126-4","volume":"17","author":"DD Price","year":"1983","unstructured":"Price DD, McGrath PA, Rafii A et al (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17:45\u201356","journal-title":"Pain"},{"key":"1237_CR21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0304-3959(86)90095-3","volume":"25","author":"C Aun","year":"1986","unstructured":"Aun C, Lam YM, Collett B (1986) Evaluation of the use of visual analogue scale in Chinese patients. Pain 25:215\u2013221","journal-title":"Pain"},{"key":"1237_CR22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"1237_CR23","first-page":"13","volume":"87","author":"FL Greene","year":"2002","unstructured":"Greene FL (2002) The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 87:13\u201315","journal-title":"Bull Am Coll Surg"},{"key":"1237_CR24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0277-5379(90)90136-H","volume":"26","author":"U Metzger","year":"1990","unstructured":"Metzger U (1990) Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference. Eur J Cancer 26:753\u2013755","journal-title":"Eur J Cancer"},{"key":"1237_CR25","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.2004.05.063","volume":"22","author":"AB Benson 3rd","year":"2004","unstructured":"Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408\u20133419","journal-title":"J Clin Oncol"},{"key":"1237_CR26","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP, Wieand HS, O\u2019Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198\u20132204","journal-title":"J Clin Oncol"},{"key":"1237_CR27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/SPC.0b013e32832b7df5","volume":"3","author":"S Tesfaye","year":"2009","unstructured":"Tesfaye S (2009) Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 3:136\u2013143","journal-title":"Curr Opin Support Palliat Care"},{"key":"1237_CR28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1152\/jn.2001.85.5.2293","volume":"85","author":"F Grolleau","year":"2001","unstructured":"Grolleau F, Gamelin L, Boisdron-Celle M et al (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293\u20132297","journal-title":"J Neurophysiol"},{"key":"1237_CR29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuro.2006.04.010","volume":"27","author":"LE Ta","year":"2006","unstructured":"Ta LE, Espeset L, Podratz J et al (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992\u20131002","journal-title":"Neurotoxicology"},{"key":"1237_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/diabetes.52.1.165","volume":"52","author":"AM Schmeichel","year":"2003","unstructured":"Schmeichel AM, Schmelzer JD, Low PA (2003) Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52:165\u2013171","journal-title":"Diabetes"},{"key":"1237_CR31","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-0597-0","volume-title":"Sensory mechanisms of the spinal cord","author":"WD Willis","year":"1991","unstructured":"Willis WD, Coggeshall RE (1991) Sensory mechanisms of the spinal cord. Plenum, New York"},{"key":"1237_CR32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.ne.07.030184.001521","volume":"7","author":"AI Basbaum","year":"1984","unstructured":"Basbaum AI, Fields HL (1984) Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7:309\u2013338","journal-title":"Annu Rev Neurosci"},{"key":"1237_CR33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tips.2004.10.002","volume":"25","author":"R Suzuki","year":"2004","unstructured":"Suzuki R, Rygh LJ, Dickenson AH (2004) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25:613\u2013617","journal-title":"Trends Pharmacol Sci"},{"key":"1237_CR34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1017\/S0140525X97251484","volume":"20","author":"TJ Coderre","year":"1997","unstructured":"Coderre TJ, Katz J (1997) Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 20:404\u2013419, discussion 435\u2013513","journal-title":"Behav Brain Sci"},{"key":"1237_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(02)00368-8","volume":"100","author":"K Ren","year":"2002","unstructured":"Ren K, Dubner R (2002) Descending modulation in persistent pain: an update. Pain 100:1\u20136","journal-title":"Pain"},{"key":"1237_CR36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.104.070656","volume":"311","author":"S Iyengar","year":"2004","unstructured":"Iyengar S, Webster AA, Hemrick-Luecke SK et al (2004) Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311:576\u2013584","journal-title":"J Pharmacol Exp Ther"},{"key":"1237_CR37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","volume":"10","author":"SM Stahl","year":"2005","unstructured":"Stahl SM, Grady MM, Moret C et al (2005) SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10:732\u2013747","journal-title":"CNS Spectr"},{"key":"1237_CR38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.pain.2004.05.010","volume":"110","author":"MC Rowbotham","year":"2004","unstructured":"Rowbotham MC, Goli V, Kunz NR et al (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110:697\u2013706","journal-title":"Pain"},{"key":"1237_CR39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","volume":"25","author":"FP Bymaster","year":"2001","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871\u2013880","journal-title":"Neuropsychopharmacology"},{"key":"1237_CR40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpsychires.2004.04.011","volume":"39","author":"SK Brannan","year":"2005","unstructured":"Brannan SK, Mallinckrodt CH, Brown EB et al (2005) Duloxetine 60\u00a0mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39:43\u201353","journal-title":"J Psychiatr Res"},{"key":"1237_CR41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30\u201339","journal-title":"J Natl Cancer Inst"},{"key":"1237_CR42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200645030-00003","volume":"45","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Meijerman I, Beijnen JH et al (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253\u2013285","journal-title":"Clin Pharmacokinet"},{"key":"1237_CR43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2006.02.015","volume":"45","author":"JC Hewes","year":"2006","unstructured":"Hewes JC, Riddy D, Morris RW et al (2006) A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. J Hepatol 45:263\u2013270","journal-title":"J Hepatol"},{"key":"1237_CR44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CAD.0b013e328323a7a8","volume":"20","author":"V Masek","year":"2009","unstructured":"Masek V, Anzenbacherova E, Machova M et al (2009) Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 20:305\u2013311","journal-title":"Anticancer Drugs"},{"key":"1237_CR45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/dmd.30.4.391","volume":"30","author":"N Hanioka","year":"2002","unstructured":"Hanioka N, Ozawa S, Jinno H et al (2002) Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 30:391\u2013396","journal-title":"Drug Metab Dispos"},{"key":"1237_CR46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00228-003-0641-z","volume":"59","author":"JY Park","year":"2003","unstructured":"Park JY, Kim KA (2003) Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol 59:407\u2013409","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1237-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-011-1237-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1237-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T17:57:40Z","timestamp":1560448660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-011-1237-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,4]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s00520-011-1237-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,4]]}}}